Director
Gilead Sciences, Inc.
Indrajeet Singh, PhD, is currently a Director at Gilead Sciences. Before joining Gilead in 2020, he was previously employed at Johnson and Johnson, Amgen and Abbott Labs. He has more than 11 years of industry experience in various therapeutic areas including oncology, hematology and neuroscience. Majority of his clinical pharmacology experience is in oncology space where he worked on ADC (antibody drug conjugates), various CD3 redirection platforms including CAR-T and Bi-specifics antibodies (duo-body, DART, BiTE), monoclonal antibodies, oligonucleotides and small molecules with focus on early and late clinical pharmacology strategy and regulatory submissions.
He earned his bachelor’s degree in Chemical Engineering from the Indian Institute of Technology, Kharagpur, India. After that, he moved to the US where he pursued his PhD in Chemical and Biological Engineering from the University at Buffalo (UB), NY and was awarded with National Perkin Scholarship by Society of Chemical Industry America for his PhD research work on thrombosis and hemostasis. After his PhD, He completed a post-doctoral fellowship in the Department of Pharmaceutical Sciences at UB (2009-2011) focusing on PK/PD modeling and simulations. He published in several peer-reviewed journals, presented his work at several clinical conferences, and chaired multiple external scientific sessions. He has been an invited guest speaker at several conferences including an FDA workshop on CAR-T cell therapy.